Special Issue "Personalized Prevention of Gallbladder Cancer"
Deadline for manuscript submissions: 25 August 2022 | Viewed by 2753
Interests: Statistics for Molecular Medicine; Personalized Prevention; Gallbladder Cancer; Risk Biomarkers
Gallbladder cancer (GBC, ICD-10 diagnosis code C23) is an aggressive malignancy that accounts for the majority of biliary tract tumours, especially in low- and middle-income countries. Resection of tumours confined to the mucosa is currently the only potentially curative treatment, but early diagnosis is difficult because early symptoms are inconspicuous and nonspecific. On the other hand, GBC develops over a long period of time and surgical removal of the gallbladder in individuals at high-risk of GBC or affected by pre-neoplastic lesions offers a good opportunity for personalized GBC prevention.
This Special Issue of the Journal of Personalized Medicine aims to highlight the current status and recent developments in the broad field of personalized GBC prevention. Articles on the identification and characterization of novel risk and early disease biomarkers, on the causal mechanisms linking lifestyle, culture and behaviour to GBC development, and on novel opportunities for targeted therapy of incidental tumours are particularly welcome.
Prof. Dr. Justo Lorenzo Bermejo
Dr. Dominique Scherer
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Personalized Medicine is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2000 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- gallbladder cancer
- personalized prevention
- risk biomarker
- primary prevention
- secondary prevention/early detection
- tertiary prevention/avoidance of gallbladder cancer progression